Olga Saez-Martinez

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 06, 2026

HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.

Journal: ESMO open

Published: April 11, 2026

Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 05, 2026

Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Clinical features and management for CDK4/6 inhibitor-DILI.

Journal: JHEP reports : innovation in hepatology

Published: January 29, 2026

Clinical features and management for CDK4/6 inhibitor-DILI.

Journal: JHEP reports : innovation in hepatology

Published: January 29, 2026

Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989].

Journal: ESMO open

Published: January 06, 2026

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 18, 2025

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Journal: ESMO open

Published: December 17, 2025

Clinical and biomarker predictors of early and late recurrence in hormone receptor-positive breast cancer.

Journal: BMC cancer

Published: December 09, 2025

Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK).

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 26, 2025

Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.

Journal: Breast cancer research and treatment

Published: November 04, 2025

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.

HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.

Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study.

Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study.

Clinical features and management for CDK4/6 inhibitor-DILI.

Clinical features and management for CDK4/6 inhibitor-DILI.

Clinical features and management for CDK4/6 inhibitor-DILI.

Clinical features and management for CDK4/6 inhibitor-DILI.

Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989].

Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989].

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Clinical and biomarker predictors of early and late recurrence in hormone receptor-positive breast cancer.

Clinical and biomarker predictors of early and late recurrence in hormone receptor-positive breast cancer.

Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK).

Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK).

Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.

Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.